Search

Your search keyword '"Sézary syndrome"' showing total 142 results
Start Over Descriptor "Sézary syndrome" Journal european journal of cancer
142 results on '"Sézary syndrome"'

1. Radiotherapy in cutaneous lymphomas: Recommendations from the EORTC cutaneous lymphoma tumour group

Author

Elsayad, Khaled, Guenova, Emmanuella, Assaf, Chalid, Nicolay, Jan P., Trautinger, Franz, Stadler, Rudolf, Waldstein, Cora, Boterberg, Tom, Meijnders, Paul, Kirova, Youlia, Dobos, Gabor, Duque-Santana, Victor, Riggenbach, Elena, Elsheshtawy, Wael, Niezink, Anne, Papadavid, Evangelia, Scarisbrick, Julia, Vermeer, Maarten, Neelis, Karen J., Bagot, Martine, Battistella, Maxime, Quaglino, Pietro, Knobler, Robert, Kempf, Werner, Maklad, Ahmed, Adeberg, Sebastian, Kouloulias, Vassilis, Simontacchi, Gabriele, Corradini, Stefanie, König, Laila, Eich, Hans Theodor, Cowan, Richard, and Correia, Dora

Published
2024
Full Text
View/download PDF

6. A-167 Durable disease control with low-dose total skin electron beam therapy combined with maintenance treatment for patients with erythrodermic mycosis fungoides and Sézary syndrome.

Author

Elsayad, K., Kandler, C., Siats, J.J., Pepper, N., Danzer, M.F., Dobos, G., Livingstone, E., Melchers, S., Kleemann, J., Hyun, J., Pföhler, C., von den Driesch, P., Nicolay, J.P., Stadler, R., and Eich, H.T.

Subjects
*SEZARY syndrome, *MYCOSIS fungoides, *ELECTRONS, *CONFERENCES & conventions, *COMBINED modality therapy, *RADIATION doses
Published
2024
Full Text
View/download PDF

7. A-214 Evaluation of Sézary cell marker expression and cell death behavior upon in vitro treatment by flow cytometry in Sézary Syndrome patients.

Author

Melchers, S., Roemer, M., Albrecht, J.D., Assaf, C., von Gugelberg, C., Guenova, E., Klemke, C.-D., Moritz, R.K., Schlaak, M., Stadler, R., Wehkamp, U., Wobser, M., Albrecht, T., Goerdt, S., Schneider, S., and Nicolay, J.P.

Subjects
*FLOW cytometry, *SEZARY syndrome, *TUMOR markers, *CONFERENCES & conventions, *CELL lines, *GENE expression, *CELL death
Published
2024
Full Text
View/download PDF

8. A-181 Staphylococcus aureus induces drug resistance in cancer T cells in Sézary syndrome.

Author

Vadivel, C.K., Willerslev-Olsen, A., Namini, M.R.J., Zeng, Z., Yan, L., Danielsen, M., Gluud, M., Pallesen, E.M.H., Wojewoda, K., Osmancevic, A., Hedebo, S., Chang, Y.-T., Lindahl, L.M., Koralov, S.B., Geskin, L.J., Bates, S.E., Iversen, L., Litman, T., Bech, R., and Wobser, M.

Subjects
*T cells, *DRUG resistance in cancer cells, *STAPHYLOCOCCUS aureus, *SEZARY syndrome, *CONFERENCES & conventions
Published
2024
Full Text
View/download PDF

9. A-201 Patient-reported symptoms and HRQL of MF and SS patients receiving mogamulizumab over 24 weeks: interim results from the PROSPER study.

Author

Scarisbrick, J., Arumainathan, A., Cowan, R., DeSimone, J., Esler, C., Geskin, L.J., Goldaniga, M., Violetti, S. Alberti, Mheidly, K., Morsia, E., Muniesa, C., Musiek, A., Nassi, L., Pagano, L., Pileri, A., Pujol, R.M., Quint, K., Rozati, S., Sandilands, K., and Shinohara, M.

Subjects
*THERAPEUTIC use of monoclonal antibodies, *MYCOSIS fungoides, *SEZARY syndrome, *CONFERENCES & conventions, *QUALITY of life, *SYMPTOMS
Published
2024
Full Text
View/download PDF

18. A-298 RESMAIN: Results of a multicenter, randomized, double blind, placebo-controlled trial to evaluate RESminostat for MAINtenance treatment in advanced stage Mycosis fungoides or Sézary syndrome.

Author

Stadler, R., Woei-A-Jin, S., Dummer, R., Mitteldorf, C., Papadavid, E., Quaglino, P., Ortiz, P., Guenova, E., Abe, R., Busschots, A.M., and Scarisbrick, J.

Subjects
*ANTINEOPLASTIC agents, *MYCOSIS fungoides, *SEZARY syndrome, *CONFERENCES & conventions, *RANDOMIZED controlled trials, *CANCER chemotherapy, *DRUG efficacy
Published
2024
Full Text
View/download PDF

20. A-200 Mogamulizumab in patients with mycosis fungoides or Sézary syndrome: Update on the German non-interventional MINT study.

Author

Assaf, C., Booken, N., Schlaak, M., Dobos, G., Oymanns, M., Klespe, K.-C., Nicolay, J., Wobser, M., Ocker, L., Haferkamp, S., Hassel, J., Menzer, C., Terheyden, P., Klemke, C.-D., Dippel, E., Weishaupt, C., Garzarolli, M., Wohlrab, J., Hoffmann, F., and Bachinger, A.

Subjects
*THERAPEUTIC use of monoclonal antibodies, *MYCOSIS fungoides, *SEZARY syndrome, *TREATMENT effectiveness, *CONFERENCES & conventions
Published
2024
Full Text
View/download PDF

23. A-122 Lacutamab in Patients with Relapsed and Refractory Sézary Syndrome: Results from the TELLOMAK Phase 2 Trial.

Author

Bagot, M., Kim, Y.-H., Geskin, L.J., Ortiz-Romero, P.L., Kim, E., Mehta-Shah, N., Dereure, O., Oro, S., Beylot-Barry, M., Dalle, S., Jacobsen, E., Lansigan, F., Ram-Wolff, C., Khodadoust, M., Battistella, M., Gru, A., Moins-Teisserenc, H., Zinzani, P.L., Viotti, J., and Paiva, C.

Subjects
*THERAPEUTIC use of antineoplastic agents, *THERAPEUTIC use of monoclonal antibodies, *CANCER relapse, *DRUG resistance in cancer cells, *SEZARY syndrome, *CONFERENCES & conventions, *DRUG efficacy, *EVALUATION
Published
2024
Full Text
View/download PDF

26. A-175 Toward patient-tailored immunotherapy: targeting the TCR idiotype of clonal Sézary lymphomas.

Author

Herrero-Alonso, M., Marin, A.V., Megino, R. Fernádez, Estévez-Benito, I., Arguedas, D. Chacón, Ramiro, A., Domínguez, M., Moreno, I., Alonso-Vega, M.L. Gaspar, Cortegano, I., de Andrés, B., Viñuela-Martín, M., Real-Arévalo, I., Subiza, J.L., González-García, S., Arellano, I., Alarcón, B., Romero, P.L. Ortiz, and Regueiro, J.R.

Subjects
*T cells, *IMMUNOTHERAPY, *SEZARY syndrome, *CONFERENCES & conventions, *INDIVIDUALIZED medicine
Published
2024
Full Text
View/download PDF

28. Maintenance therapy in patients with mycosis fungoides or Sézary syndrome: A neglected topic.

Author

Stadler, Rudolf and Scarisbrick, Julia J.

Subjects
*HEMATOPOIETIC stem cell transplantation, *MYCOSIS fungoides, *QUALITY of life, *SEZARY syndrome, *T-cell lymphoma, *EPIGENOMICS
Abstract

In advanced-stage cutaneous T-cell lymphoma (CTCL), the current therapeutic options rarely provide long-lasting responses, leaving allogenic stem-cell transplantation the only potentially curative option for highly selected patients. Until today, there are no standardised strategies for maintenance therapy in patients with CTCL who achieved disease control. Moreover, evidence-based treatment options or drugs that are approved for maintenance treatment in advanced stages after remission induction are still lacking. Patients require maintenance options that provide a good safety profile, are convenient to apply and do not negatively affect their health-related quality of life. However, carrying out large-scale, controlled studies is challenging in CTCL. In addition to information on the concept of maintenance therapy, this review provides an update on current and emerging approaches that target maintenance treatment in advanced-stage CTCL. After all, the group of potentially interesting maintenance therapy candidates, especially for patients in advanced stage, includes not only immunomodulating and phototherapeutic modalities that have been used already for many decades but also newer systemic therapies, including epigenetic modifiers. • Short therapeutic response rate with chemotherapy is limited to a few months. • Maintenance therapy must be selected, effective, available, and well tolerated. • Treatment in advanced MF, SS between USA/non USA did not influencing survival outcome. • Besides classical end-points SD, PR, CR, HRQol the length of TTNT is of relevance. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

29. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2023.

Author

Latzka, Johanna, Assaf, Chalid, Bagot, Martine, Cozzio, Antonio, Dummer, Reinhard, Guenova, Emmanuella, Gniadecki, Robert, Hodak, Emmilia, Jonak, Constanze, Klemke, Claus-Detlev, Knobler, Robert, Morrris, Stephen, Nicolay, Jan P., Ortiz-Romero, Pablo L., Papadavid, Evangelia, Pimpinelli, Nicola, Quaglino, Pietro, Ranki, Annamari, Scarisbrick, Julia, and Stadler, Rudolf

Subjects
*THERAPEUTIC use of interferons, *THERAPEUTIC use of monoclonal antibodies, *CONSENSUS (Social sciences), *DISEASE progression, *MYCOSIS fungoides, *LIFE expectancy, *SEZARY syndrome, *MECHLORETHAMINE, *QUALITY of life, *MEDICAL societies
Abstract

On behalf of the EORTC Cutaneous Lymphoma Tumours Group (EORTC-CLTG) and following up on earlier versions published in 2006 and 2017 this document provides an updated standard for the treatment of mycosis fungoides and Sézary syndrome (MF/SS). It considers recent relevant publications and treatment options introduced into clinical practice after 2017. Consensus was established among the authors through a series of consecutive consultations in writing and a round of discussion. Treatment options are assigned to each disease stage and, whenever possible and clinically useful, separated into first- and second line options annotated with levels of evidence. Major changes to the previous version include the incorporation of chlormethine, brentuximab vedotin, and mogamulizumab, recommendations on the use of pegylated interferon α (after withdrawal of recombinant unpegylated interferons), and the addition of paragraphs on supportive therapy and on the care of older patients. Still, skin-directed therapies are the most appropriate option for early-stage MF and most patients have a normal life expectancy but may suffer morbidity and impaired quality of life. In advanced disease treatment options have expanded recently. Most patients receive multiple consecutive therapies with treatments often having a relatively short duration of response. For those patients prognosis is still poor and only for a highly selected subset long term remission can be achieved with allogeneic stem cell transplantation. Understanding of the disease, its epidemiology and clinical course, and its most appropriate management are gradually advancing, and there is well-founded hope that this will lead to further improvements in the care of patients with MF/SS. • Mycosis fungoides and Sézary syndrome are variants of cutaneous T cell lymphomas. • Prognosis and choice of treatment depend on disease stage. • Treatment recommendations are provided by the EORTC Cutaneous Lymphoma Tumour Group. • Considerations for supportive care and treatment of elderly patients are included. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

30. Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force.

Author

Scarisbrick, Julia J., Hodak, Emmilia, Bagot, Martine, Stranzenbach, Rene, Stadler, Rudolf, Ortiz-Romero, Pablo L., Papadavid, Evangelia, Evison, Felicity, Knobler, Robert, Quaglino, Pietro, and Vermeer, Maarten H.

Subjects
*BLOOD, *FLOW cytometry, *MYCOSIS fungoides, *SEZARY syndrome
Abstract

Our current mycosis fungoides (MF) and Sézary Syndrome (SS) staging system includes blood-classification from B0-B2 for patch/plaque/tumour or erythroderma based on manual Sézary counts but results from our EORTC survey confirm these are rarely performed in patch/plaque/tumour MF, and there is a trend towards using flow cytometry to measure blood-class. Accurately assigning blood-class effects overall stage and the ‘global response’ used to measure treatment responses in MF/SS and hence impacts management. The EORTC Cutaneous Lymphoma Task Force Committee have reviewed the literature and held a Workshop (June 2017) to agree a definition of blood-class according to flow cytometry. No large study comparing blood-class as defined by Sézary count with flow cytometry has been performed in MF/SS. The definition of blood-class by flow cytometry varies between publications. Low-level blood involvement occurs in patch/plaque/tumour much less than erythroderma (p < 0.001). The prognostic relevance of blood involvement (B1 or B2) in patch/plaque/tumour is not known. Studies have not shown a statistically worse difference in prognosis in erythrodermic MF patients with low-level blood involvement (IIIB) versus those without (IIIA), but Sezary patients who by definition have a leukaemic blood picture (staged IVA1 or higher) have a worse prognosis. For consistency flow, definition for blood-class must be an objective measurement. We propose absolute counts of either CD4+CD7-or CD4+CD26-where B0<250/μL, B1 = 250/μl–<1000/μL and B2≥1000/μL plus a T-cell blood clone. Fluctuations between B0 and B1 should not be considered in the treatment response criteria until further prognostic information is known. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

31. P-205 - Toxic epidermal necrolysis possibly associated with mogamulizumab in a patient with Sézary syndrome.

Author

Lazaridou, Ingrid, Calvani, Julien, Annabi, Elissa, Moins-Teisserenc, Hélène, Ta, Van Anh, Rivet, Jacqueline, Ram-Wolff, Caroline, Dumont, Maëlle, Mahevas, Thibault, Vignon-Pennamen, Marie-Dominique, Mourah, Samia, Bouaziz, Jean-David, Louveau, Baptiste, Bagot, Martine, Battistella, Maxime, and De Masson, Adèle

Subjects
*THERAPEUTIC use of monoclonal antibodies, *TOXIC epidermal necrolysis, *MONOCLONAL antibodies, *CONFERENCES & conventions, *RISK assessment, *SEZARY syndrome, *DISEASE risk factors
Published
2023
Full Text
View/download PDF

33. P-191 - Allogeneic hematopoietic stem cell transplantation in patients with advanced mycosis fungoides and Sézary syndrome: 2023 update of the Milan experience.

Author

Onida, Francesco, Cavallaro, Francesca, Violetti, Silvia Alberti, Goldaniga, Maria, Barbullushi, Kordelia, Galassi, Giulia, Serpenti, Fabio, Cecchi, Nicola, Bellani, Valentina, Cassanello, Giulio, Galli, Nicole, Versino, Francesco, Rampi, Nicolò, Bosi, Alessandro, Croci, Giorgio Alberto, Simontacchi, Gabriele, Berti, Emilio, and Saporiti, Giorgia

Subjects
*HOMOGRAFTS, *MYCOSIS fungoides, *CONFERENCES & conventions, *SEZARY syndrome, *TREATMENT effectiveness, *HEMATOPOIETIC stem cell transplantation
Published
2023
Full Text
View/download PDF

34. P-194 - Real world evidence: assessing the clinical efficacy of mogamulizumab in mycosis fungoides and Sézary syndrome using time to next treatment.

Author

Scarisbrick, Julia, Mathe, Noma, Shah, Farida, Rooke, Bethanie, Peterknecht, Elizabeth, Murray, Duncan, Irwin, Clive, and Pugh, Matthew

Subjects
*THERAPEUTIC use of monoclonal antibodies, *EVALUATION of medical care, *MYCOSIS fungoides, *TIME, *CONFERENCES & conventions, *SEZARY syndrome, *TREATMENT effectiveness, *CLINICAL medicine, *EVALUATION
Published
2023
Full Text
View/download PDF

35. P-184 - Health-related quality of life (HRQL) in cutaneous T-cell lymphoma: burden of disease and patient characteristics from a post-hoc analysis of a phase 3 trial in mycosis fungoides and Sézary syndrome.

Author

Romero, Pablo, Nixon, Annabel, Kim, Youn H., Molloy, Kevin, Quaglino, Pietro, Scarisbrick, Julia, Thornton, Susan, Sandilands, Kerry, Liu, Jennifer, Williams, Angela, and Shinohara, Michi

Subjects
*MYCOSIS fungoides, *HEALTH status indicators, *CONFERENCES & conventions, *SEZARY syndrome, *QUALITY of life, *CUTANEOUS T-cell lymphoma
Published
2023
Full Text
View/download PDF

36. P-173 - A real-world international observational study of mogamulizumab in adult patients with mycosis fungoides and Sézary syndrome (PROSPER study NCT05455931).

Author

Scarisbrick, Julia, Williams, Angela, Ardigò, Marco, Arumainathan, Arvind, Cowan, Richard, DeSimone, Jennifer, Geskin, Larisa, Goldaniga, Maria, Hashmi, Shahrukh, James, Eleanor, Musiek, Amy, Muniesa, Cristina, Nassi, Luca, Pileri, Alessandro, Vallverdu, Ramon Pujol, Quint, Koen, Rozati, Sima, Rupoli, Serena, Shinohara, Michi, and Pagano, Livio

Subjects
*THERAPEUTIC use of monoclonal antibodies, *MYCOSIS fungoides, *CONFERENCES & conventions, *SEZARY syndrome, *ADULTS
Published
2023
Full Text
View/download PDF

37. P-175 - Progressive peripheral polyneuropathy in a patient with Sézary syndrome.

Author

Pappa, Vasiliki, Vaiopoulos, Aristeidis, Lampadaki, Kyriaki, Koumourtzis, Marios, Fanouraki, Stella, Zis, Panagiotis, Velonakis, Georgios, Thomopoulos, Thomas, Tsakatikas, Sergios, Lakiotaki, Eleftheria, Korkolopoulou, Pinelopi, and Papadavid, Evangelia

Subjects
*PERIPHERAL nervous system, *CONFERENCES & conventions, *SEZARY syndrome, *POLYNEUROPATHIES
Published
2023
Full Text
View/download PDF

41. P-169 - Real-world effectiveness of mogamulizumab in patients with Sézary syndrome or mycosis fungoides in Spain and Portugal: The MIBERIC study.

Author

Romero, Pablo Ortiz, Vallverdú, Ramón Pujol, Cravo, Mariana, Cuba, Iván Quispe, Escudero, Andrea Combalia, Rodríguez Núñez, Rosa María, Montserrat, Cristina Muniesa, Fernández-de-Misa, Ricardo, Mascuñano, Raúl Córdoba, Rodríguez, Daniel Nieto, Velasco, Mar Llamas, Cabral, Renata, Redondo, Carlos Ulibarrena, Martitegui, Xabier Martín, Garnelo, Julia Blanco, and Villar, Alfonso Mouriz

Subjects
*THERAPEUTIC use of monoclonal antibodies, *MYCOSIS fungoides, *CONFERENCES & conventions, *SEZARY syndrome
Published
2023
Full Text
View/download PDF

42. O-152 - Role of total skin electron beam radiotherapy at relapse after allogeneic transplant in mycosis fungoides and Sézary syndrome.

Author

Simontacchi, Gabriele, Mattioli, Chiara, Onida, Francesco, Marrazzo, Livia, Cela, Doruntina, Vagge, Stefano, Schiavone, Concetta, Grandi, Vieri, Pimpinelli, Nicola, Mangoni, Monica, Olmetto, Emanuela, Chilà, Debora, and Livi, Lorenzo

Subjects
*HOMOGRAFTS, *MYCOSIS fungoides, *CANCER relapse, *CONFERENCES & conventions, *SEZARY syndrome
Published
2023
Full Text
View/download PDF

43. O-151 - Non-myeloablative allogeneic stem cell transplantation using TSEBT, TLI and ATG for mycosis fungoides and Sézary syndrome: results from a large single centre cohort.

Author

Thomas, Bjorn, Palanicawandar, Renuka, Whittaker, Sean, Child, Fiona, Wain, Mary, Sim, Van, Szydlo, Richard, Mangar, Stephen, Olavarria, Eduardo, Muzamil, Asif, Kanfer, Edward, and Morris, Stephen

Subjects
*MYCOSIS fungoides, *ANTILYMPHOCYTIC serum, *CONFERENCES & conventions, *SEZARY syndrome, *PROTON therapy, *HEMATOPOIETIC stem cell transplantation
Published
2023
Full Text
View/download PDF

44. O-146 - Efficacy and tolerability of mogamulizumab in patients with mycosis fungoides or Sézary syndrome: retrospective and real-world data from centres of the French Study Group of Cutaneous Lymphoma.

Author

Beylot-Barry, Marie, Quereux, Gaelle, Nardin, Charlée, Duval-Modeste, Anne-Bénédicte, Dereure, Olivier, Dalac-Rat, Sophie, Dobis, Gabor, Pham-Ledard, Anne, Ram-Wolff, Caroline, D'Incan, Michel, Grange, Florent, Braniste, Viorica, and Bagot, Martine

Subjects
*THERAPEUTIC use of monoclonal antibodies, *THERAPEUTIC use of antineoplastic agents, *DRUG efficacy, *DRUG tolerance, *MYCOSIS fungoides, *CONFERENCES & conventions, *SEZARY syndrome, *EVALUATION
Published
2023
Full Text
View/download PDF

45. O-145 - Mogamulizumab in patients with mycosis fungoides or Sézary syndrome: interim analysis of the German non-interventional MINT study.

Author

Assaf, Chalid, Booken, Nina, Dippel, Edgar, Garzarolli, Marlene, Haferkampt, Sebastian, Schlaak, Max, Dobos, Gabor, Ocker, Lennart, Terheyden, Patrick, Klemke, Claus-Detlev, Nicolay, Jan, Wobser, Marion, Wohlrab, Johannes, Bachinger, Andreas, Danish, Azeem, and Jadasz, Janusz

Subjects
*THERAPEUTIC use of monoclonal antibodies, *THERAPEUTIC use of antineoplastic agents, *DRUG efficacy, *MYCOSIS fungoides, *CONFERENCES & conventions, *SEZARY syndrome, *EVALUATION
Published
2023
Full Text
View/download PDF

46. O-143 - RESMAIN: results of a multicenter, randomized, double blind, placebocontrolled trial to evaluate resminostat for maintenance treatment in advanced stage mycosis fungoides or Sézary syndrome.

Author

Stadler, Rudolf, Woei-A-Jin, Sherida, Dummer, Reinhard, Mitteldorf, Christina, Papadavid, Evangelia, Quaglino, Pietro, Ortiz-Romero, Pablo Luis, Guenova, Emmanuella, Abe, Riichiro, Ramelyte, Egle, Busschots, Anne-Marie, Knobler, Robert, Suzuki, Kenta, Danhauser-Riedl, Susanne, and Scarisbrick, Julia

Subjects
*RESEARCH, *MYCOSIS fungoides, *CONFERENCES & conventions, *SEZARY syndrome, *TREATMENT effectiveness
Published
2023
Full Text
View/download PDF

47. O-137 - Oncogenic drivers in NF-kappaB pathway-related elements provide candidate targets for future targeted therapies in Sézary syndrome.

Author

Espinosa, Lluís, Lobo, Teresa, Andrades, Evelin, Iglesias, Arnau, González, Jèssica, Bellosillo, Beatriz, Bigas, Anna, Pujol, Ramon, and Gallardo, Fernando

Subjects
*THERAPEUTIC use of antineoplastic agents, *NF-kappa B, *ANTINEOPLASTIC agents, *CONFERENCES & conventions, *CELLULAR signal transduction, *SEZARY syndrome, *PHARMACODYNAMICS
Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results